BBP - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Products ETF (BBP)
BBP, the Virtus LifeSci Biotech Products ETF, has a mixed but generally solid overall rating driven by several financially strong biotech holdings alongside more speculative names. Strong contributors like Rigel Pharmaceuticals, Kiniksa Pharmaceuticals, and Halozyme support the fund’s quality through robust revenue growth and positive earnings outlooks, although Halozyme’s high leverage and some bearish technical signals add caution. Weaker, higher-risk holdings such as Omeros and Verastem, which face significant losses and financial instability, along with the fund’s concentration in the volatile biotech sector, are the main factors that hold back the rating and increase risk.
BBP vs. SPDR S&P 500 ETF (SPY)
- AUM
- 127.72M
- Region
- North America
- Expense Ratio
- 0.34%
- Beta
- 0.92
- Issuer
- Virtus
- Inception Date
- Dec 17, 2014
- Dividend Yield
- 0.07%
- Asset Class
- Equity
- Index Tracked
- LifeSci Biotechnology Products Index
BBP Summary
Virtus LifeSci Biotech Products ETF (BBP) is a fund that follows the LifeSci Biotechnology Products Index, focusing on U.S. biotech companies developing and selling new medicines and treatments. It holds a mix of well-known names like Moderna along with smaller, innovative drug makers, giving investors a way to tap into the growth potential of cutting-edge health care. Someone might invest in BBP to gain targeted exposure to the biotech theme and diversify within the health care sector. A key risk is that biotech stocks can be very volatile and may rise or fall sharply based on drug trial results and market sentiment.
How much will it cost me?
This ETF has an annual expense ratio of 0.34%, which means you’ll pay about $3.40 per year for every $1,000 you invest. That cost is a bit higher than the average broad-market index ETF because BBP is a more specialized, sector-focused fund that requires more research and active oversight.
What would affect this ETF?
BBP could benefit if demand for new vaccines, gene therapies, and other biotech treatments grows, especially as its U.S. health care holdings like Moderna and other drug developers gain from medical breakthroughs and supportive regulation. On the downside, this ETF is highly sensitive to changes in drug pricing rules, clinical trial setbacks, and shifts in investor sentiment toward riskier growth stocks, which can be amplified by interest rate increases or a weaker U.S. economy.
BBP Top 10 Holdings
BBP is a pure play on U.S. biotech, with performance largely steered by a handful of volatile names. Moderna has been rising on renewed optimism around its pipeline, giving the fund a helpful lift. Iovance and Halozyme are also in the driver’s seat, with steady-to-strong momentum backed by solid growth stories. On the flip side, Zai Lab and Xeris look more like dead weight for now, with mixed to lagging performance and ongoing financial concerns. Overall, this is a concentrated bet on high-risk, high-reward biotech innovators.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MRNA | Moderna | 5.25% | $6.72M | $79.39B | 680.08% | 59Neutral |
 IOVA | Iovance Biotherapeutics | 4.45% | $5.69M | $6.24B | 531.17% | 50Neutral |
 VSTM | Verastem | 3.21% | $4.11M | $1.22B | 15.83% | 44Neutral |
 OMER | Omeros | 2.46% | $3.14M | $1.18B | 126.85% | 40Underperform |
 HALO | Halozyme | 2.43% | $3.10M | $14.53B | 95.14% | 73Outperform |
 XERS | Xeris Pharmaceuticals | 1.98% | $2.53M | $1.86B | 12.24% | 46Neutral |
 KNSA | Kiniksa Pharmaceuticals | 1.85% | $2.37M | $5.69B | 119.70% | 72Outperform |
 RIGL | Rigel | 2.00% | $2.56M | $932.31M | 70.89% | 78Outperform |
 ONC | BeOne Medicines | 1.85% | $2.36M | $42.25B | 16.05% | 61Neutral |
 ZLAB | Zai Lab | 1.88% | $2.40M | $2.72B | -10.48% | 48Neutral |
BBP Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBP, the sentiment is Negative. The current price of 104.89 is above the 20-day moving average (MA) of 103.10, above the 50-day MA of 104.78, and above the 200-day MA of 92.00, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 47.58 is Neutral, neither overbought nor oversold. The STOCH value of 41.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BBP.
BBP Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BBP | $104.89 | $107.00(2.02% Upside) | $127.72M | 0.34% | 60Neutral |
 RSPH | $39.35 | $42.25(7.37% Upside) | $972.71M | 0.40% | 71Outperform |
 PJP | $126.36 | $155.32(22.92% Upside) | $555.09M | 0.58% | 70Neutral |
 XPH | $63.96 | $105.79(65.40% Upside) | $438.96M | 0.35% | 57Neutral |
 PBE | $100.74 | $122.44(21.53% Upside) | $429.04M | 0.59% | 70Outperform |
 SBIO | $55.48 | $109.29(97.00% Upside) | $182.66M | 0.50% | 46Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BBP | Virtus LifeSci Biotech Products ETF | 104.89 | 31.65 | 43.22% | |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.35 | 9.19 | 30.49% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 126.36 | 32.38 | 34.45% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 63.96 | 15.64 | 32.37% | |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 100.74 | 29.10 | 40.62% | |
| SBIO | ALPS Medical Breakthroughs ETF | 55.48 | 11.26 | 25.46% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.